Noninvasive method to reduce vitreous reflux following intravitreal injection
| Autor: | Raouf Gaber, Mina Nassif, Wesam S Shalaby, Osama Sorour |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Journal of the Egyptian Ophthalmological Society, Vol 116, Iss 1, Pp 24-27 (2023) |
| Druh dokumentu: | article |
| ISSN: | 2090-0686 2314-6648 |
| DOI: | 10.4103/ejos.ejos_93_22 |
| Popis: | Aim To investigate the role of pre-injection antiglaucoma medications as a noninvasive method to prevent reflux following intravitreal injection (IVI). Patients and methods This single-center prospective randomized study included patients who were planned to receive an IVI of anti-vascular endothelial growth factor ranibizumab 0.05 ml for macular edema for diabetic macular edema, branch retinal vein occlusion, or choroidal neovascular membrane. Patients were randomized into five groups: no intervention (group 1), pre-injection topical brimonidine (group 2), pre-injection oral acetazolamide (Diamox) (group 3), pre-injection topical brimonidine and oral Diamox (group 4), and pre-injection paracentesis (group 5). The primary outcomes were the occurrence and degree of reflux following IVI. In addition, the evaluation of conjunctival bleb estimated the degree of reflux. Patient self-rated pain and early complications were secondary outcome measures. Results A total of 150 eyes of 150 patients were included. Vitreous reflux occurred in 13 (43%), 14 (46.7%), 19 (63.3%), six (20.0%), and four (13.3%) eyes in groups 1–5, respectively (P |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|